#Alamar Biosciences #NULISAqpcr #Alzheimer's Research

Alamar Biosciences Launches NULISAqpcr™ BD-pTau217 Test

In an exciting development for Alzheimer's disease research, Alamar Biosciences has recently introduced the NULISAqpcr™ BD-pTau217 test. This innovative testing method marks a significant advancement in the non-invasive identification of brain-specific biomarkers, particularly focusing on the phosphorylated tau protein (pTau217), which is a key indicator of Alzheimer's and related tauopathies.

The announcement was made on October 10, 2025, from Fremont, California, where Alamar Biosciences operates as a premier company specializing in targeted proteomics. The NULISAqpcr™ BD-pTau217 test is notable for its exceptional sensitivity and specificity, setting a new benchmark for accurately quantifying this crucial biomarker in blood samples without the need for more invasive procedures such as cerebrospinal fluid extraction or PET imaging studies. This breakthrough allows for large-scale population studies and long-term clinical research, paving the way for much-needed advancements in therapeutic approaches to Alzheimer’s and other neurodegenerative disorders.

Redefining Neurological Biomarker Measurement

Dr. Yuling Luo, the founder, president, and CEO of Alamar Biosciences, emphasized how this test redefines the possibilities for quantitative biomarker assessment specific to the central nervous system. He stated, "By eliminating interference from tau protein originating from the peripheral nervous system, researchers can now detect significant changes occurring in the brain earlier and with greater precision." This capability could revolutionize the way scientists track disease progression and evaluate potential treatments, making it easier to identify candidates for clinical trials aimed at modifying the disease’s course.

Experts in the field have lauded the advances provided by this technology. Professor Jonathan Schott, a neurologist at University College London, praised the efficiency of the pTau217 marker tests, suggesting that the one-parameter format of the NULISAqpcr™ test may prove just as effective as established methods, yet with a lower number of samples yielding undetectable results. “In research settings, having a direct measurement of brain-derived pTau protein with multi-parameter tests offers promising results for asymptomatic patients with high Alzheimer's-related pathogens,